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Abstract
Purpose This review aimed to determine the prevalence, causes and risk factors of medicine-related problems (MRPs) in patients
with liver cirrhosis.
Methods Eight online databases were searched up to 30 September 2018 with no start date. Appropriate Critical Appraisal Skills
Programme tools were used to assess the quality of included studies.
Results An overall 16 quantitative and 11 qualitative studies were included in the review. Methodological quality of the included
studies was variable. Mean frequency of MRPs reported in the quantitative studies ranged from 14 to 23.4%. The most frequent
causes of MRPs included drug interactions, inappropriate dosing and use of contraindicated drugs. The qualitative analysis
identified three themes: patient-related factors, healthcare professionals’ related factors and stigma associated with liver cirrhosis.
Conclusion MRPs were found to be prevalent in patients with liver cirrhosis. Factors contributing toMRPs in liver cirrhosis were
not limited to medicines’ effects and interactions but included healthcare systems and patients. Therefore, management of liver
cirrhosis should not be limited to providing an effective medicine therapy and should take into account the patients’ behaviour
towards the condition.
Keywords Liver cirrhosis . Medicine-related problems . Quantitative . Qualitative . Systematic review
Introduction
Liver cirrhosis is a major chronic disease that is associated
with high morbidity and mortality [1]. In the USA, the inci-
dence of liver cirrhosis was around 0.27% corresponding to
approximately 634,000 adults [2]. The Global Burden of
Disease reported that more than one million people died
worldwide due to liver cirrhosis in 2010 compared with
676,000 deaths in 1980 [3]. Patients affected by liver cirrhosis
are at an increased risk of developing multiple complications
and consequently have reduced life expectancy [4]. For in-
stance, ascites is one of the most common complications of
liver cirrhosis [5] and is responsible for 15% of deaths in
patients with liver cirrhosis within 1 year of their diagnosis
[6]. Similarly, a recent cohort study on hospital readmissions
in patients diagnosed with liver cirrhosis suggests that about
13% of the admissions within 30 days were caused by com-
plications of the disease [7].
It is also important to highlight that the drug therapy in
liver cirrhosis is complex due to the pathophysiological
changes associated with the disease that alter the pharmaco-
kinetics of drugs [8, 9]. For instance, the reduced albumin
synthesis in liver cirrhosis [10] can increase the risk of po-
tential drug toxicity of protein-bound drugs due to their in-
creased plasma concentration. Similarly, the metabolic ca-
pacity is also compromised in liver cirrhosis due to the re-
ductionofmetabolisingenzymes such asCYP450 in the liver
and hence impairment in hepatic blood flow [11]. Thus, pa-
tientswith liver cirrhosis aremore sensitive tomedicines and
their side effects with evidence suggesting that around 30%
of patients with liver cirrhosis exhibit adverse drug reactions
(ADRs) and have a high risk of hospitalisation [12]. These
findings indicate that patients with liver cirrhosis require
close monitoring and dose adjustment to ensure rational use
of medicines and to avoid the risk of ADRs and other
medicine-related problems (MRPs).
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AMRP is defined as Ban event or a circumstance involving
drug therapy that actually or potentially interferes with the
desired health outcome^ [13]. The other major categories of
MRPs besides ADRs include adverse drug events (ADEs) and
medication errors (MEs) [14]. In addition to making an appro-
priate selection of drug therapy, it is also important to under-
stand other factors that might influence the rational use of
medicines in a complex disease such as liver cirrhosis. Some
of these factors include patient knowledge and understanding
about the disease and its management [15]. To the authors’
knowledge, no review to date has been conducted to deter-
mine the underlying causes and risk factors of MRPs in pa-
tients with liver cirrhosis. This review, therefore, aims to sys-
tematically investigate the prevalence, causes and risk factors
of MRPs in cirrhotic patients and to explore factors influenc-
ing the medicine use from both patients and healthcare pro-
viders’ perspectives.
Methods
As this review included both quantitative and qualitative stud-
ies which investigated medicine use and MRPs in patients
with cirrhosis, the pragmatic approach was found to be the
most appropriate philosophical paradigm that rationalises the
analysis process and hence answers the objectives of this re-
view [16]. The systematic review was conducted in accor-
dance with the recommendation of Preferred Reporting
Items for Systematic Reviews and Meta-Analysis (PRISMA)
[17].
Search strategy
Eight online databases (PubMed, EMBASE, CINAHL,
Scopus, Web of Science, The British Library, PsycInfo
and Google Scholar) were systematically and comprehen-
sively searched from inception to September 2018. Search
terms included medicine (drug/medication)–related prob-
lems, medicine (drug/medication) use, liver (hepatic) cir-
rhosis, chronic liver diseases, attitude, knowledge, adher-
ence and non-adherence (Appendix 1). Additional rele-
vant terms were also handpicked from the literature dur-
ing the review. Boolean operators (OR, AND, NOT) were
utilised to combine concepts and refine the width and
depth of search to capture available evidence. Grey liter-
ature was searched using Open Grey and EBSCO.
Furthermore, scooping in Google and a manual search
of references cited in retrieved articles were performed
by the reviewer (AA) to identify relevant studies.
Reference lists of retrieved articles and relevant review
articles were manually examined for further relevant
studies.
List of definitions
An adverse drug event (ADE) is defined as Ban injury
resulting from the use of a drug^ [18]. An adverse drug reac-
tion (ADR) is Ban appreciably harmful or unpleasant reaction,
resulting from an intervention related to the use of a medicinal
product^ [18]. A cause of anMRP is defined as Bthe action (or
lack of action) that leads up to the occurrence of a potential or
real problem. There may be more than one cause for a
problem^ [14]. Comorbidities are defined as chronic illnesses
or diseases which require long-term treatment [19] and coexist
alongside the main diagnosis. Medicine adherence is defined
as the extent to which the patient’s drug-taking behaviour (in
terms of taking medication) coincides with the agreed recom-
mendation [20]. A medication error (ME) is defined as
Bfailure in the treatment process that leads to, or has the po-
tential to lead to, harm to the patient^ [21]. AnMRP is defined
as an event or circumstance involving drug therapy that actu-
ally or potentially interferes with desired health outcomes [14,
22]. Polypharmacy is defined as the use of five or more med-
ications [23]. A risk factor is an action (or lack of action) that
facilitates the occurrence of an MRP [24]. The rational use of
drugs comprises Bproviding patients with the right medica-
tions in correct doses that are appropriate for their individual
indications, for an adequate period of time, and at the lowest
cost^ [25].
Study selection
Inclusion criteria
The review included both quantitative and qualitative studies
published in English language and in peer-reviewed journals.
Studies were eligible for inclusion if they included patients (≥
18 years old) diagnosed with liver cirrhosis or chronic liver
diseases and investigated the frequency and causes of MRPs
in cirrhotic patients. Qualitative studies reporting beliefs,
knowledge, attitudes and perception of patients/healthcare
professionals towards liver cirrhosis and its treatment were
also included.
Exclusion criteria
Studies were excluded if their main focus was liver diseases
other than liver cirrhosis such as hepatitis, encephalopathy or
hepatic carcinoma. Review articles, editorials and commentar-
ies were not included in the review.
Data extraction and analysis
Data extraction was carried out by one reviewer (AA) and was
independently verified by a second reviewer (AH). Any dif-
ferences were resolved by the involvement of a third reviewer
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(EC). Items extracted from the studies included study title,
author name, year of study, country, study design, sample size
and results.
Data analysis was conducted over two stages where two
methods were applied to the findings of the review being
textual narrative analysis (for quantitative data) and thematic
analysis (for qualitative data).
The textual narrative approach encompassed recording the
aim, characteristics, quality and outcomes (whether ADEs,
ADRs, MEs or MRPs) for each study in order to draw con-
clusion from the findings. The reported prevalence of ADRs
andMEs were grouped as two categories under MRPs. Due to
the heterogeneity among the studies, it was not possible to
report the means, and only prevalence per study was calculat-
ed. Furthermore, the medicines reported in the included stud-
ies were grouped into main medicine classes including anal-
gesics (paracetamol, opioids and non-steroidal anti-inflamma-
tory drugs (NSAIDs)), antimicrobials, diuretics, proton pump
inhibitors (PPIs) and sedatives.
Data from the qualitative studies were synthesised using
thematic synthesis technique reported by Thomas and
Harden [26]. The synthesis was conducted in three phases:
phase 1: line-by-line coding of the findings of the primary
studies, phase 2: developing sub-themes through organising
the codes and phase 3: generating themes. This approach was
then repeated, and studies were reread to ensure transparent
integration of all concepts related to our research question and
objectives. The naming of themes and sub-themes was either
as original studies or under different names, where it was
conceptually appropriate. The emerged themes offered an in-
terpretation to address our review’s objectives and go beyond
the content of the results of the primary studies [26].
Quotations from the articles were used to illustrate the identi-
fied themes (Table 3).
Quality assessment
Critical Appraisal Skills Programme (CASP) tools were used
to assess the quality of both quantitative and qualitative stud-
ies [34]. Since there is no CASP checklist available for cross-
sectional studies, the Quality of Observational Cohort and
Cross-Sectional Studies quality assessment tool (Appendix
2) was used to assess the quality of the included cross-
sectional studies [35].
The items assessed for the quality of qualitative studies
included study aims, methods, validity and reliability of data
collection and appropriateness of the study design. While for
the quantitative studies, the assessment items included appro-
priateness of the study design, the risk of bias, statistical issues
and data generalisability.
The included studies were categorised based on a grading
criteria that took into account the number of questions that
were fulfilled based on the above-mentioned tools: that is,
high quality (***) for a score of 7–10 points, medium quality
(**) if scored 4–6 points and low quality (*) if scored 0–3
points. Although the low-quality studies were not excluded,
their findings were interpreted with caution.
Results
Study selection
The initial search yielded 503 studies. A further seven studies
were identified through manual searches of reference lists
bringing the total to 510 studies (Fig. 1). Three hundred
sixty-one studies were left after removal of duplicates and
application of inclusion/exclusion criteria. Of these, 102 stud-
ies were excluded after reviewing abstracts and titles. The
remaining 47 studies were further assessed, and another 20
were excluded as they did not meet the inclusion/exclusion
criteria. Twenty-seven studies were included in the review. Of
these, 16 were quantitative and 11 were qualitative studies.
Quantitative studies
A total of 16 quantitative studies with 5636 participants were
included in the review [15, 27–30, 32, 33, 36–43]. Of these 16
studies, three were conducted in Australia [36–38] and the
USA [15, 39, 40], two each in Chile [41, 42] and Indonesia
[33, 43], and one each from Switzerland [27], India [28], UK
[30], Pakistan [29] and Netherlands [32]. All included studies
used an observational study design (Table 1).
Prevalence of MRPs
Nine studies reported the incidence of the MRPs [12, 27,
29, 32, 33, 38, 41–43]. Seven of the nine studies reported
the incidence using total patients as a denominator. The
mean prevalence of MRPs reported in these studies
ranged from 4.21 to 38.4%. The remaining two studies
used the total number of prescriptions as a denominator
with the mean prevalence ranging from 8.33 to 22%.
Owing to the heterogeneity between the methods of mea-
suring MRPs, it was not possible to calculate the mean
prevalence across all nine studies. Moreover, definitions
of MRPs varied among the included studies which made it
difficult to conduct meta-analysis.
The most common category of MRPs reported in the stud-
ies was ADRs. It was reported in six out of the nine included
studies, while the ME was the other common category of
MRP reported in three retrospective studies. No study report-
ed data on ADEs.
Eur J Clin Pharmacol
Causes and risk factors of MRPs
Causes in the evaluated studies were actions that directly
triggered the occurrence of an MRP. Seven studies report-
ed the causes of MRPs [12, 27, 29, 32, 33, 38, 41]. The
reported causes of MRPs included drug-drug interactions
[12, 27, 29, 33], inappropriate dosing [12, 29, 32, 41],
contraindications [32, 38] and inappropriate choice of
drug therapy [29]. In addition, risk factors contributed to
MRPs’ incidence without having a direct causal relation-
ship with MRPs. Polypharmacy was the most commonly
reported risk factor for liver cirrhosis [27, 41, 42] where
MRPs were more prevalent in patients taking a median of
seven to nine medicines. This was followed by associated
comorbidities such as ascites, portal hypertension and pri-
or hepatic encephalopathy [27, 42]. Moreover, the sever-
ity of the disease [12, 42] and the longer duration of
hospital stay (more than 12 days) [41, 42] further contrib-
uted to MRPs. Other reported risk factors included old
age (range 39–62 years) [27] and impaired renal function
(renal dysfunction considered when blood urea nitrogen
was above 25 mg/100 ml and/or creatinine clearance was
below 80 ml/min) [27].
Medicine classes
Nine studies reported data on medicine classes
suspected to be associated with DRPs [12, 27, 29, 32,
33, 38, 41–43]. Diuretics including furosemide and
spironolactone were the most commonly reported medi-
cines attributed to MRPs [12, 25, 36–38, 40], followed
by sedatives including benzodiazepines [12, 32, 38, 41,
42], analgesics including paracetamol and NSAIDs [12,
27, 32, 38] and antimicrobials including pencillins [38,
42, 43], proton pump inhibitors [12, 32, 38] and potas-
sium salts [41, 42]. Other less frequently reported med-
icine classes included calcium channel blockers [43],
statins [32] and iron [32].
Qualitative studies
A total of 11 qualitative studies explored potential factors
influencing the medicine use in cirrhotic patients [31,
44–53]. Table 2 illustrates the characteristics of the qual-
itative studies, of which three were conducted in Iran
[44–46] and the USA [31, 47, 48], two in Denmark [49,
50] and UK [51, 52] followed by one in Netherlands [53].
All the included studies were published between 2013 and
2015 and represented the view of 601 participants, of
which 472 were patients with liver cirrhosis and 129 were
healthcare professionals including specialist doctors and
hepatology nurses. Thematic synthesis of the qualitative
data identified three key themes related to medicine use in
liver cirrhosis: (1) patient-related factors, (2) healthcare-
related factors and (3) stigma (Table 3).
Fig. 1 Data extraction flow diagram
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Patient-related factors
The patient-related factors included lack of knowledge, finan-
cial pressure, lack of motivation, patients’ beliefs and treat-
ment issues.
Patients reported lack of knowledge about the nature of the
disease, causes and complications [47, 49, 51]. Some patients
held their doctors responsible for their poor knowledge about
the disease [45, 52]. Patients indicated the need for more in-
formation about their medications and their possible side ef-
fects [46, 53]. Furthermore, some patients also reported lack
of awareness about the risk factors associated with liver cir-
rhosis such as alcohol and drug abuse. However, some of
these patients admitted that although they were aware of the
risk factors, they still maintained an unhealthy lifestyle [47].
Lack of patients’ motivation towards their disease
management including treatment was reported in two
studies [44, 48]. The chronic nature of the disease and
associated hospitalisation could have contributed to pa-
tients’ despair and hopelessness with regard to the out-
look of their illness. Furthermore, patients’ beliefs about
liver cirrhosis might also had changed their perception
about the disease and its cure. Some patients believed
that the disease is from (a will from) God [45] and the
treatment will not help them as the only cure comes
from God particularly during the advanced stages of
the disease [45, 46]. However, for some, their faith
and belief in God was a source of support that encour-
aged them to deal with the disease and adhere to their
treatment [46].
Table 2 Characteristics of the qualitative studies
Study Country Title Study
population
Method of
data collection
Method of
analysis
Study
quality
Kimbell
et al. [52]
UK To understand the experiences and support
needs of people with advanced liver disease
and those of their lay and professional carers
to inform improvements in the supportive
and palliative care of this rapidly growing
but currently neglected patient group
37 Multiperspective serial
qualitative interviews
Grounded theory
technique
***
Burnham
et al. [31]
USA To explore knowledge, attitudes, behaviours
and barriers to care among patients with
chronic liver disease
13 3 separate one time 60-min
focus groups
Editing analysis
method
**
Shabanloei
et al. [44]
Iran To clarify cirrhotic patients’ perception
of their treatment
15 Semi-structured in-depth inter-
views
Content analysis
approach based on
Graneheim and
Lundman’s
methods
***
Vaughn-Sandler
et al. [48]
USA To determine the prevalence and consequences
of stigma in patients with cirrhosis
300 Cross-sectional survey Methods of
qualitative
description
**
Borgsteede
et al. [53]
Netherlands To explore the patient’s needs on information
about medication at hospital discharge
28 Qualitative semi-structured in-
terview
Thematic content
analysis
*
Abdi et al. [46] Iran To investigate the disease experiences
of liver cirrhosis
10 Phenomenological qualitative
in-depth interview
Colaizzi’s seven-step
analysis method
***
Groenkjaer et al.
[50]
Denmark To explore hepatology nurses’ knowledge and
education in the oral care and oral health
assessments of patients with liver cirrhosis
94
Hepatol-
ogy
nurses
Questionnaire Content analysis *
Beste et al. [47] USA To explore primary care providers’ attitudes and
self-reported roles in caring for patients with
cirrhosis
24 Structured qualitative
telephone interview
Editing analysis style
by Crabtree and
Miller
[thematically
coded response]
**
Goldworthy
et al. [51]
UK To assess baseline patient knowledge and to test
whether a condition-specific multimedia
screencast could improve this
52 Questionnaire at baseline then
repeated (at least 1 month)
after condition-specific
multimedia screencast
Service quality improvement
study
– *
Shabanloei
et al. [44]
Iran To discover and define the perceived stigma by
cirrhotic patients
15 Semi-structured in-depth inter-
views
Content analysis
approach based on
Graneheim and
Lundman’s
methods
**
Fagerstrom et al.
(2017) [49]
Denmark To explore the areas of life situation and
self-care among patients suffering from liver
cirrhosis with complications
13 Semi-structured interview Inductive content
analysis
**
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Healthcare-related factors
The healthcare-related factors identified in the studies includ-
ed barriers to accessing healthcare, communication between
patients and healthcare providers (HCPs) and challenges faced
by HCPs.
Lack of accessibility to healthcare was reported in four
studies [31, 45, 47, 52]. From HCP perspectives, barriers
to healthcare access involved factors related to patients,
such as low motivation for treatment and low adherence.
Financial constraints by patients were also one of the bar-
riers reported by HCPs [31]. Patients discussed the high
cost of medical services and problems with insurance
companies with their HCPs [47]. Furthermore, fears of
experiencing side effects, lack of awareness about the
availability of support services [31] together with the long
gaps between their appointments were some of the other
barriers to healthcare access [31, 47, 52].
Importance of effective communication between pa-
tients and HCPs was highlighted in four studies [31, 46,
49, 52]. It was reported to have a positive impact on
treatment as it improves patient’s adherence and their un-
derstanding of the condition and helps to forge a relation-
ship based on trust between patients and HCPs [31, 46].
Some patients, however, reported lack of effective com-
munication with HCPs due to a shorter consultation time
and the use of medical jargons by HCPs [52] .
Furthermore, poor communication and collaboration be-
tween HCPs and patients had resulted in discontinuity of
patient care in some instances [49].
Table 3 Emerging themes/sub-themes from the qualitative studies
Themes Sub-themes Quotations
Patient-related
factors
Lack of knowledge BI had little information about the disease. If it was more, I would not consume my drugs
causally. I would pay more attention to the disease. I would not let it grow so much and
damage my liver. I thought it was like a cold. Gradually I’d recover. Since there were not
any symptoms, I thought there would not be any problems^ [27].
Financial burden BI’m a tenant and do not have a good financial condition and my disease is a real burden… I
do not receive any financial support and my treatment costs are really high^ [28].
Lack of motivation (despair) BDeath is approaching me. I should try to be alive and not seek treatment. The disease eats
my body. Patients think they have a short time for survival and it
becomes shorter every moment^ [27].
Beliefs BThe disease is caused by the will of God and as a test and there is no reason to be upset and
cry^ [27].
Treatment issues (factors related to
the medication adherence)
BAt 10 o’clock, I have two tablet of spironolactone and 3 other drugs whose names I do not
know, on the whole, I have six drugs in the morning, six in the evening, and four at night.
I take many drugs. I cannot manage them on time. I go out sometime or I forgot them
completely. Or I cannot buy the drugs or I cannot find them. Thus, I either do not use
them or have few of them^ [29].
Healthcare-related
factors
Accessibility
(or barriers to care)
BThe challenge from the patient, which applies every where- urban, rural, tertiary, or
primary- is that many patients are reluctant to participate full in therapy or to make life
style changes which would facilitate the therapy. Particularly giving up alcohol but also
just coming in for appointments and taking their medicines, which do not make feel
good. So I think patient compliance or patient adherence or patient participation, what-
ever you want to call it, is a big barrier^ [30].
Communication BWhat they are saying is, Bright, your potassium level’s at such and such, your sodium
level’s at such and such,^what else, Byour blood count was this, your blood pressure was
that.^ (…) And they do not actually tell me what it means. It is good? Is it bad? Is this
happy medium? I do not know^ [31].
Challenges of HCPs BWell, without the training background, we just keep an eye on their liver function and
make sure that they are getting their annual ultrasound screen, but other than that you
know we usually rely on Hepatology^ [30].
Stigma Misconception BManymedical personnel (Doctors, nurses, nutritionists) are uninformed about liver disease
that is non-alcoholic related and assume it is. I feel pain involved is undertreated and not
believed by medical personnel due to thinking I already have a substance abuse problem.
Why do not they just automatically test us for drugs/ ETOH then we can move on to my
care and concerns. Not the concerns of ETOH^ [32].
Discrimination (avoidance) BPeople know little. I do not like anybody to know about my disease. I’ve seen lots of
discrimination for it^ [32].
Consequences BOne of the fears of my life is disclosure of my disease. Always they think that addicts or
criminals suffer from this^ [33].
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Challenges faced by HCPs were reported in three studies
[31, 50, 52]. Unclear responsibilities were one of the chal-
lenges reported by HCPs in particular by primary care physi-
cians (PCPs). PCPs, in general, reported their awareness about
their roles in managing cirrhotic patients that included patient
monitoring (symptoms and lab tests) and education [31].
However, some of them were reluctant to take decisions on
the management or to contradict the specialists’ opinions [31,
52]. Reliance on specialist recommendation was common
among PCPs [52]. Other challenges reported in the studies
included the need for further training by hepatology nurses
particularly on ADR recognition and management of oral
health of patients with liver cirrhosis [50].
Stigma related to cirrhosis
The concept of stigma included negative attitudes (miscon-
ception and discrimination) and negative consequences.
Misconceptions about the disease were reported in four
studies [44, 47, 48, 52]. Some patients linked the condition
to substance abuse [44, 47] while others perceived the disease
to be contagious [44, 48]. These misconceptions were com-
monly reported to have developed fromwithin the social com-
munity [47, 48, 52]. Cirrhosis was perceived to be a self-
caused condition due to the adoption of an unhealthy lifestyle
[47, 48]. Furthermore, patients with cirrhosis also reported
discriminations from both HCPs and general public. Some
patients reported to have a limited social circle as some mem-
bers of the public avoided interacting with them due to the risk
of getting infectious [44, 48]. Some patients also preferred to
deny the treatment and medical appointments offered by
HCPs to avoid the risk of receiving negative judgement and
discrimination from HCPs and close community [47].
The negative impact and consequences of the disease were
reported in four studies [44, 47, 48, 52]. These included the
psychological effects of the disease on patients including de-
pression, low self-esteem and reduced quality of life [44, 48].
Discussion
To the authors’ knowledge, this is the first systematic review
that brings together evidence from both quantitative and qual-
itative studies to gain an insight into MRPs in patients with
liver cirrhosis. The findings of this review suggest that man-
agement of liver cirrhosis should not only be limited to the
provision of safe and effective drug therapy but should also
expand to improving the understanding of patients about the
disease.
MRPs with a mean prevalence of 14–23.4% were reported
to constitute a significant health problem in patients with cir-
rhosis. The mean prevalence reported in this review was
higher compared with 8.3% reported in a previous review that
involved 15 studies [54]. The higher prevalence of MRPs
reported in the current review could be attributed to the phar-
macodynamic and pharmacokinetic changes associated with
liver cirrhosis that consequently increases the incidence of
MRPs [55] compared with other chronic conditions. Drug-
drug interactions and inappropriate dosing were identified as
the two major causes of MRPs in the review. Other less fre-
quently reported causes included contraindicated drugs, un-
suitable selection and erratic discontinuation of medicines.
Similar findings have also been reported in a previous review
involving hospitalised patients, which reported that around
17% of all documented MRPs were due to drug-drug interac-
tions [56]. The use of lowest effective dose and dose adjust-
ment according to renal and liver function are among some of
the strategies that can prevent the incidence of dose-dependent
MRPs [56].
Polypharmacy followed by associated comorbidities, se-
verity of liver cirrhosis and length of hospital stay were among
the most commonly reported risk factors for MRPS in this
review. These findings are consistent with the findings of a
cross-sectional study, which concluded that the number of
prescribed drugs is a predictor of MRPs [57]. Polypharmacy
is a known risk factor for both ADRs and MEs in many
chronic diseases such as liver cirrhosis as they are often asso-
ciated with comorbidities [58]. A study involving 827 patients
conducted in hospital settings suggested that the number
MRPs reported for each patient is linearly associated with
the number of medications used at hospital admission [59].
The study further reported that a one unit increase in the num-
ber of medicines prescribed was associated with an increase in
the number of MRPs by 8.6%.
Diuretics and sedatives were among the major medicine
classes that were suspected to be associated with MRPs in
patients with liver cirrhosis. A previous study that investigated
the prescribing patterns and drug use in patients with liver
cirrhosis highlighted that diuretics are one of the frequently
prescribedmedications in managing the complications of liver
cirrhosis such as ascites [60]. The study also reported a signif-
icant association between diuretics chiefly furosemide and
ADRs reported in the study population suggesting the need
of careful monitoring of these drugs. Similarly, a review of 21
studies also implicated diuretics along with anti-inflammatory
drugs in MRP-related hospital admissions [61]. Analgesics
including paracetamol and NSAIDs were the other major
medicine classes associated with MRPs. Paracetamol is gen-
erally considered to be safe in patients with liver cirrhosis but
at a reduced dosage of 3 g/day [62]. In contrast, NSAIDs
should be avoided in cirrhotic patients particularly during ad-
vanced stages due to the established risk of renal impairment
and gastrointestinal bleeding [62, 63]. Furthermore, NSAIDs
are metabolised byCYP enzymes that have reduced activity in
cirrhosis and consequently raises NSAID plasma levels and
increases the risk of adverse events [62].
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Patients widely reported poor knowledge and under-
standing about the disease and its risk factors, associat-
ed complications and treatment. This lack of awareness
has also been reported previously in an American study
which suggested that patients with liver disease have
limited knowledge about the safety of acetaminophen
for pain management that can put them at risk of
undermedication or overdose [64]. Another American
study that involved liver transplant patients suggested
that patients with a better understanding of their treat-
ment and medication regimen were more likely to ad-
here to their treatment and can avoid the risk of
hospitalisation [65]. Healthcare professional-led educa-
tional interventions including booklets, leaflets and
videos have been associated with significant (< 0.001)
improvement in patients’ knowledge and adherence to
treatment in liver cirrhosis [30].
The review identified some of the challenges faced by
healthcare professionals in managing cirrhotic patients
that could negatively impact the control of the disease.
Primary care physicians commonly raised uncertainty
about roles and responsibilities as some of them believed
that management of cirrhosis was a specialists’ responsi-
bility [31]. Primary care physicians reported the need for
further training to gain skills and confidence to enable
them to manage cirrhotic patients particularly during ad-
vanced stages. An Italian study suggested that provision
of training programs to primary care physicians allowed
them to make early referrals to specialists that conse-
quently improved the outcomes of patients with hepato-
cellular carcinoma [66, 67]. The increased prevalence of
cirrhosis necessitates the involvement of primary care
physicians in managing liver cirrhosis. Efforts should be
directed towards the provision of training and support
with the aim of improving physicians’ knowledge and
expertise about the optimal management of the disease.
This review has some limitations. The review did not in-
clude studies published in languages other than English that
could have led to exclusion of valuable and relevant data. The
review explored medicine use from patients’ and healthcare
professionals’ perspectives only. The inclusion of family and
caregivers in the review would have provided a more broad
and extensive insight on the medicine use. Owing to the het-
erogeneity in the included studies, meta-analysis could not be
conducted.
Conclusion
The findings of this review support the need of provi-
sion of safe and effective drug therapy together with
patient-centred education to improve the medicine use
in patients with liver cirrhosis. Furthermore, emotional
and social support should also be provided to patients to
improve their psychological well-being and outlook
about the disease.
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Appendix 1
Search strategies used in the major electronic
databases
Embase:
1) Medicine use.mp.
2) Medicine related problems.mp. Or drug related prob-
lems. Or adverse drug event. Or adverse drug reaction.
Or medication error.
3) 1 or 2
4) Exp liver cirrhosis / or Hepatic cirrhosis/
5) chronic liver diseases *.mp.
6) 4 or 5
7) Exp Knowledge / or beliefs *.mp.
8) attitude *.mp.
9) 3 and 6 and 7 and 8.
10) limit 9 to (English language and (adult <18 to 100 years)
Medline Ovid:
1) Medicine use.mp.
2) Medicine related problems / or drug related
problems.mp. Or adverse drug event. Or adverse drug
reaction. Or medication error.
3) liver cirrhosis.mp. or exp Hepatic cirrhosis /
4) 1 or 2 or 3
5) 1 or 3
6) Exp Knowledge / or beliefs *.mp.
7) attitude *.mp.
8) 5 and 6 and 7
9) 4 and 6 and 7
10) limit 8 to (English language and (Ball adult (18 plus
years)^
Eur J Clin Pharmacol
Appendix 2
Table 4 Quality assessment tool for observational cohort and cross-sectional studies
Criteria Yes No Other (CD, NR, NA)*
1. Was the research question or objective in this paper clearly stated? Yes No Other (CD, NR, NA)*
2. Was the study population clearly specified and defined? Yes No Other (CD, NR, NA)*
3. Was the participation rate of eligible persons at least 50%? Yes No Other (CD, NR, NA)*
4. Were all the subjects selected or recruited from the same or similar
populations (including the same time period)? Were inclusion and
exclusion criteria for being in the study prespecified and
applied uniformly to all participants?
Yes No Other (CD, NR, NA)*
5. Was a sample size justification, power description or variance
and effect estimates provided?
Yes No Other (CD, NR, NA)*
6. For the analyses in this paper, were the exposure(s) of interest
measured prior to the outcome(s) being measured?
Yes No Other (CD, NR, NA)*
7. Was the timeframe sufficient so that one could reasonably expect
to see an association between exposure and outcome if it existed?
Yes No Other (CD, NR, NA)*
8. For exposures that can vary in amount or level, did the study
examine different levels of the exposure as related to the outcome
(e.g., categories of exposure or exposure measured as continuous variable)?
Yes No Other (CD, NR, NA)*
9. Were the exposure measures (independent variables) clearly
defined, valid, reliable and implemented consistently
across all study participants?
Yes No Other (CD, NR, NA)*
10. Was the exposure(s) assessed more than once over time? Yes No Other (CD, NR, NA)*
11. Were the outcome measures (dependent variables) clearly
defined, valid, reliable and implemented consistently
across all study participants?
Yes No Other (CD, NR, NA)*
12. Were the outcome assessors blinded to the exposure status of participants? Yes No Other (CD, NR, NA)*
13. Was loss to follow-up after baseline 20% or less? Yes No Other (CD, NR, NA)*
14. Were key potential confounding variables measured and
adjusted statistically for their impact on the relationship
between exposure(s) and outcome(s)?
Yes No Other (CD, NR, NA)*
Quality rating (good, fair or poor) (see guidance)
Rater #1 initials:
Rater #2 initials:
Additional comments (If POOR, please state why):
file://mds/USER/A-F/alhamiam/Desktop/Quality-Assessment-Tool-for-Observational-Cohort-and-Cross-Sectional-Studies-NHLBI-NIH.pdf
CD cannot determine, NA not applicable, NR not reported
Table 5 CASP tool for qualitative studies
1. Was there a clear statement of the aims of the research? Yes Cannot tell No
2. Is a qualitative methodology appropriate? Yes Cannot tell No
3. Was the research design appropriate to research? Yes Cannot tell No
4. Was the recruitment strategy appropriate to the aims of the research? Yes Cannot tell No
5. Was the data collected in a way that addressed the research issue? Yes Cannot tell No
6. Has the relationship between researcher and participants been adequately considered? Yes Cannot tell No
7. Have ethical issues been taken into consideration? Yes Cannot tell No
8. Was the data analysis sufficiently rigorous? Yes Cannot tell No
9. Is there a clear statement of findings? Yes Cannot tell No
10. How valuable is the research?
https://casp-uk.net/wp-content/uploads/2018/01/CASP-Qualitative-Checklist-2018.pdf
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